inserm french national institute of health and medical research
DESCRIPTION
Inserm French National Institute of Health and Medical Research. Created in 1964 from the National Institute of Hygiene and Hospital Research. Working through the Ministries for Research and Health. Inserm : key figures. 335 Inserm laboratories 19 research centers. - PowerPoint PPT PresentationTRANSCRIPT
Présentation PowerPointMedical Research
Created in 1964 from the National Institute of Hygiene and Hospital Research
Working through the
DPRE-DRI
5 100 Inserm employees
335 Inserm laboratories
19 research centers
An active patent portfolio of 572 families
41 Clinical Investigation Centers (CIC)
56 start-up companies based on Inserm technology
DPRE-DRI
The French performing research organisation entirely dedicated to Biomedical & Clinical research and Public Health
All fields of research are covered in these domains
80% of the 354 research units are located in University hospitals
Research units with 8 years mandate with mid-term (4 year) evaluation. Stringent evaluation
Investigator- driven projects - AVENIR programme
Close collaboration with French Funding agencies (ANR, INCa ANRS), Sanitary agencies (InVS, AFSSAPS), Charities (AFM, …) and industrial partners.
DPRE-DRI
DPRE-DRI
Publications 1995-2005
(publications 1995 – 2005)
DPRE-DRI
New England Journal of Medicine (IF=44,016) , JAMA-Journal of the American Medical Association (23,494) and Lancet (23,878)
Science (IF=30,927) and Nature (IF=29,273)
Que les articles, ni lettres ni revues
DPRE-DRI
DPRE-DRI
DPRE-DRI
DPRE-DRI
New England Journal of Medicine (IF=44,016) , JAMA-Journal of the American Medical Association (23,494) and Lancet (23,878)
Science (IF=30,927) and Nature (IF=29,273)
Que les articles, ni lettres ni revues
DPRE-DRI
Organization
Networks focused on major public health issues
DPRE-DRI
7.5%
Handicap
5.1%
Nutrition
4.8%
AIDS
3.7%
Research laboratories being often involved in more that one domain, the overall distribution is over 100 %
DPRE-DRI
- INRIA
ex: CNG, Nanotechnology
Dedicated research Programmes :
Objectives and main characteristics:
Mutualisation and Integration
International visibility, Attractiveness
Sharing of technical facitilies
Implementation of research training programmes
International scientific council for evaluation of scientific strategy (turn-over of scientific teams : mobility, hosting new scientists or teams,…)
DPRE-DRI
Some exemples:
Graph2
2001
2001
2002
2002
2003
2003
2004
2004
2005
2005
2006
2006
2007
2007
347
2
350
4
357
5
361
6
366
8
373
9
340
19
données
Evolution des unités entre 2001 et 2007 (y compris CDR)
Années
2001
2002
2003
2004
2005
2006
2007
Années
2001
2002
2003
2004
2005
2006
2007
1) Nombre d'unités comprend les : unités, équipes, ERM, CDR
2) Nombre de CDR comprend les : unités quui sont considérés comme des CDR
&LInserm - DPRE
DPRE-DRI
National Sequencing Center
National Genotyping Center
Clinical Research Infrastructures
Competitivity clusters (Industry)
DPRE-DRI
International
National
Emergent
Main Inserm’s priorities
« Researchers » : Careers, Training & Mobility
To focus Inserm on its main mission: support both basic and clinical research; develop translational research with a multidisciplinary approach
To establish Inserm in a European and International context
To develop public/private partnerships
NEW CAREER TRACKS
To strengthen the status of young scientists; to recognize, evaluate and promote scientific qualities: high level fixed term contracts and the program AVENIR
To offer tenure positions to researchers: mid and long-term research plans
To increase research career development and mobility and foster partnerships:
INTERFACE RESEARCH GRANTS
30%: Avenir
Contrats post-doctorants 12 mois (24 mois ?)
(Postes verts)
3 ans de post-doctorat dans l’un des instituts des
NIH « intra-muros ».
de la qualité du stage post-doctoral
Contrat Junior (5ans, avec évaluation à 3 ans)
Contrat temporaire universitaire ou HU
Recrutement: EPST, Université etc ..
CR
DR
IR
Hôpital
HOPITAL
INSERM
evaluation), high level contracts
DPRE-DRI
Eligibility: Young scientists with permanent or temporary position, clinicians
Aim: To strengthen the status of young scientists; to recognize, evaluate and continuously promote scientific qualities
Each successful candidate is allocated:
A yearly budget of 60 K euros
Minimum lab space of 50 m2
Personnel: 1 post-graduate collaborator and 1 graduate student
Each successful young scientist receives a salary for 5 years
DPRE-DRI
Academic freedom
Health agencies
available to the society
European mobility ?
Hospitals: clinical research, medical issues
Health agencies: health policy issues
Universities: teaching, making scientific information available to the society
Industry: technological transfer and valorisation
European partners / European mobility (a new scheme of the Marie Curie actions - PEOPLE programme ?)
DPRE-DRI
CR
DR
Universities
Mount Sinai Medical School , New York, USA
Joint Inserm/AFM/Paris VI operation
Research theme: muscle development
Inserm Unit
Accompagnying measures:
Presently: Assistant professor, Dept of Medicine
University of Freiburg, Germany
Inserm/ULP/HUS Strasbourg joint operation
DR2 permanent position + Interphase contract HUS
Inserm unit, Avenir: in progress
Temporary contracts
Was: Clinical Scholar, Rockfeller University and Resident Clinical Pathology The New York Hospital New York, USA
Inserm/Pasteur Institute/Necker Hospital joint operation
Research theme: Dendritic cell biology/HCV/Cancer
Location: Pasteur Institute Paris
Since June 2003 : Inserm DR2 permanent position + Interphase contract AP-HP + Team Leader Pasteur Institute
Inserm Avenir Unit and Pasteur Institute Unit
Temporary contracts (junior scientists, MDs)
Assistance with housing
5 700 Inserm employees
325 Inserm laboratories
19 research centers
An active patent portfolio of 572 families
41 Clinical Investigation Centers (CIC)
56 start-up companies based on Inserm technology
DPRE-DRI
3-5 year contracts for clinicians : assistant professors and
professors, university employees
Grant paid by Inserm to hospitals and universities to be used for :
- clinical and teaching activities: temporary positions
- financing research activities
The School of Inserm
A 3 year Educational programme which leads to a Master and MD-PhD track
First year of Inserm School - Second year of Medical School :
Special School Intensive Training Session in February
June: Competitive Exam
Second year of Inserm School - Third year of Medical School
6 month full time Research Clerkship in an Inserm Research Laboratory
Third year of Inserm School - Interruption of Medical School : Clerkship in a Research Laboratory and educational program for the Master Degree
DPRE-DRI
To sponsor clinical studies and innovative therapeutic clinical trials
To ensure appropriate training of Physicians to Research skills and vice-versa
To integrate these actions in a European context:
ECRIN, Biological resource centers: Roadmap ESFRI
Innovative medecine platform
Translational research
To support development of new therapeutic molecules :
Innovative BASIC research approaches
in between : dedicated research infrastructures
To support Innovation and Biotechnology sector development
To satisfy end-users (patients) requirements
DPRE-DRI
Inserm, as a major actor of the Clinical Research in France and in Europe
To set-up an efficient Translational research towards the benefits of patients
To develop dedicated performing Research Infrastructures : ECRIN, GMP facilities platforms (innovative biomedicines), BRCs, (Roadmap ESFRI)
To sponsor clinical studies and innovative therapeutic clinical trials
To ensure appropriate training of Physicians to Research skills and vice-versa : School of Inserm
To built a continuum from Basic research to Clinical Research
DPRE-DRI
35
2006
< 2000
2000
2001
2002
2003
2004
2005
CIC-Biothérapie
Etudes et essais cliniques réalisées dans les CIC:
environ 20-30% viennent des unités
DPRE-DRI
CIC
Bichat
797 on-going Clinical trials
European and international multicentrics
About 320 000 patients expected to be included and 45 000 currently involved
120 beds devoted to clinical trials
A staff of professionals
DPRE-DRI
Gastro-Enterology-Hepatology : 9 CIC
Thrombosis : 3 CIC
Cancer
Neurosciences : 13 CIC
Paediatric : 8 CIC
DPRE-DRI
Pan-European network of Clinical research infrastructures: the ECRIN network of INSERM
ECRIN : European Clinical Research Infrastructures Network
France
EFGCP
ECRIN should be considered as a tool that will allow:
- to access research facilities certified as compliant with the GMP/GLP standards in Europe
- to access expertise in the preparation and conduct of trans-national clinical trials
- to access scientific and ethic evaluations
DPRE-DRI
to multinational studies
1 - interaction with ethics commitees
2 - interaction with competent authorities, regulatory affairs
3 - drug dispensing
DPRE-DRI
DPRE-DRI
BRCs in France
National policy of the Ministry for Research and the National Research Agency to support the development of BRCs
Lille
Caen
Rennes
Nantes
Tours
Nancy
Strasbourg
Lyon
Montpellier
Marseille
3
2
1
2
3
2
9
2
2
2
Dijon
1
Grenoble
2
Toulouse
2
Amiens
1
1
Angers
Brest
1
2
Reims
36
IDF
DPRE-DRI
Academic : valorisation, technology tranfer and dissemination of knowledge.
Biological Resources Centres
DPRE-DRI
"Service providers and repositories of the living cells, genomes of organisms, and information relating to heredity and the functions of biological systems" (O.E.C.D. definition).
Infrastructures that qualify biological samples (DNA, RNA, proteins…), provide samples for national projects and keep samples for the future (inheritage).
Biological Resources Centres
To co-ordinate European scientific programs and policies : 7th PCRD
To develop and harmonize assurance-quality standards for European BRCs : exchanges of authenticated biological materials.
Valorisation of knowledge
European Biological Resources network (EBRC)
DPRE-DRI
The European BRCs brings together:
Service and work facilities made up of collections that satisfy the EU research objectives
Conservation sites made up of patrimonial reference collections : national collections, cryobanks, rare tissue or tumour collections…
Ongoing European initiatives :
Access to "thematic" cohorts of patients (cancer, mental diseases, etc.)
Access to cohorts of healthy volunteers for prospective studies, genetic studies, etc.
The Challenges of Biomarkers
Bio-pharmaceutical industry : Valorisation of Research in partnership with industry.
DPRE-DRI
Platforms for production of therapeutic virus : Heidelberg
Perspectives : availability of GMP products
Partnership with Inserm-Transfert
IMI : Innovative Medicines for Europe
European Joint Technology Initiative (JTI) to develop new therapeutic drugs in a faster and safer way.
Inserm is the French representative in the Member states contact Group of IMI
DPRE-DRI
Organization
Networks focused on major public health issues
DPRE-DRI
National Research Programs
To bring together all parties interested in a given research area:
Research institutes
Industry
To launch calls for proposals open to the scientific community regardless of institutional affiliation
To support young investigators, scientists and clinicians
DPRE-DRI
To support new/young research teams
To support organisation of seminars and workshops : prospective studies and follow-up of actions
To identify projects that could be submitted to FP7 or some other international programmes (NIH, etc
Collaborations with the NIH: seminars and grants
To reinforce partnerships with
National Research Program on Diabetes PNRD
in collaboration with CNRS
in collaboration with INRA
Virtual Institute for Public Health Research IVRSP
National Research Program on sense organs PNRV
DPRE-DRI
PNRD
PNRC
PRNH
National Research Agency (ANR)
Created in February 2005 with a total yearly budget: around 800 M€ (approx. 25 % dedicated to Biomedical sciences)
Main objectives :
Launched calls for thematic and "free" programmes :
Cardiovascular diseases, Obesity, Diabetes
Neurosciences, psychiatry
Microbiology- Immunology
Rare diseases
Projects of scientific excellence : 370 k€ for a 3-year duration and involving 3 to 4 partners (in average)
DPRE-DRI
5652 proposals submitted
Breakdown of budget available / scientific domains :
30% Non-thematic
Specific actions and support to Partnership & Competitiveness, Young researchers (including chairs of excellence)
DPRE-DRI
In 2005 Cardiovascular, Obesity, Diabetes
Neurosciences, neurology and psychiatry
Neurosciences, neurology and psychiatry
Microbiology- Immunology- Emerging diseases
Biological Resources sampling in Health
DPRE-DRI
DPRE-DRI
DPRE-DRI
DPRE-DRI
Participation in European programmes : RTD FP & Public Health FP
Infrastructures - ESFRI (ECRIN, …)
Bilateral actions: Common Research projects - Associated laboratories - Joint-units abroad
DPRE-DRI
Inserm and
Inserm and
(2007 - 2013)
Inserm-Transfert SA
Private subsidiary of the French National Institute for Health and Medical Research (Inserm)
Created by Inserm in 2001, funded up to 4,5 M€ by Inserm and comprising actually 50 people
Increase researchers’ awareness of technology transfer and company creation
Identification and promotion of innovative projects emerging from Inserm’s laboratories
Launch of a new seed fund called “Inserm-Transfert Initiative” with three major investors in the biotech field (Sofinnova, Ventech, CDC Entreprise) - Capital amount = 4.2 M€
DPRE-DRI
International project management
21 projects under management (6 Network of Excellence, 3 Integrated Projects, 12 STREP) and 8 projects under negociation
Total budget for all projects under management over 200 million €
Creation of value by up-coming licensing and SME’s participation
Inserm-Transfert has invested 800 kEuros in 11 new biotech companies that have raised 85 million euros
600 patents' family - 60 to 90 New demands/year - 480 licensing agreements
Biotech start-up creation and Patenting
DPRE-DRI
Research networks ( EU programmes , NIH, Bill Gates etc..)
Associated laboratories
Researchers' mobility (short-medium term, Interface Contract grants)
European research networks at the bilateral level and within the EU programmes
European Associated laboratories
Cooperations between Inserm and German Partners (1)
One formal agreement with DFG : short-term exchange of researchers based on 2 years projects
538 cooperation undertaken since 1985
Main city: Berlin, Bonn, Munich, Freiburg, Heidelberg
Main thematic areas : Cellular Biology,Neurosciences, Immunology, Cancer, Genomics, Cardiovascular diseases,…
51 German Post-doc, Researchers and Fellows in the Inserm's research units in 2005
Cooperation with Freiburg:
DPRE-DRI
Cooperations between Inserm and German Partners (2)
Associated laboratories under preparation (HEGP/La Charité - Freiburg/Strasbourg)
A Joint Unit Abroad - U701 Inserm / DKFZ (J. Rommelaere - Heidelberg) - Cancer and Virotherapy
In the frame of the 6th EU Framework programme :
59 European research projects mainly in the LSH priority : 16 NoE - 27 IP - 14 STREPs - 2 CA (84 Inserm's teams - 83 German teams
Future collaborations within the FP7 :
Health priority, IMI, Infrastructures (ECRIN, BRCs)
DPRE-DRI
*
=> more than 61 common publications
Main cities: Budapest, Szeged, Debrecen
Main Partner Institutions : Hungarian Academy of Sciences, Semmelweis University, University of Debrecen etc.
Main thematic areas : Neurosciences, Cellular Biology, Molecular Biology, Cardiovascular Physiopathology, Biochemistry…
10 Hungarian Post-docs, Researchers and Fellows within Inserm's research units in 2005
DPRE-DRI
In the frame of the 6th EU Framework programme :
13 European research projects mainly in the LSH priority : 5 NoEs - 7 IPs - 1 STREP
(17 Inserm's teams - 14 +Hungarian teams)
Future collaborations within the FP7 :
Health priority, IMI, Infrastructures (ECRIN, BRCs)
*
DPRE-DRI
Co-funding by Inserm and Associated partners
Temporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts)
Networks, EU research projects
Co-funding by Inserm and Associated partners
Temporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts)
EU research projects - Networks
Lille : M. Capron U547 / Bruxelles : M. Goldman (IMI)
Associated laboratories
(under preparation)
Milan / Bordeaux
Rome / Villejuif
Rome / Nice
Ferrara / Paris
Dundee / Toulouse
Freiburg / Strasbourg
Berlin / Paris
Barcelona / Paris
Porto / Toulouse
Université de Glasgow / C. Doerig U609
DKFZ / J. Rommelaere U701
Glasgow University / C. Doerig (Inserm U609)
DKFZ / J. Rommelaere (Inserm U701)
European Associated Laboratories (LEA)
Lille Brussels:
M. Capron (Inserm U547) - M. Goldman (Univ. Libre de Bruxelles)
Toulouse Dundee:
Bordeaux Milan:
A. Bikfalvi (Inserm E 113) - L. Bello (Univ. Degli Studi)
Nice Rome:
Villejuif Paris Sud Rome:
D. Samuel (Inserm U 785) - M. Levrero (Univ. La Sapienza)
Montpellier London:
K. Ritchie (Inserm U 888) - G. Thornicroft (King’s College of London)
Strasbourg Freiburg:
T. Baumert (Inserm U 748) - H. Blum (Univ. of Freiburg)
Villejuif Paris Sud Barcelona:
Bordeaux Porto:
DPRE-DRI
Montréal
Pittsburgh
Pilot action under preparation
“2/3 base salary + 1/3 supplementation”
DPRE-DRI
Japan is the first partner of Inserm in Asia (ca. 180 collaborative projects).
An increase between 2000 and 2006 (+40%).
About 20 Japanese scientists within Inserm units each year.
2% of Inserm publications are with Japan.
Long term relationship Inserm-JSPS : 80 projects funded since 1994
Inserm-Japan
DPRE-DRI
International Associated laboratory with the RIKEN DRI on lipidomics study of membrane microdomains.
Inserm Unit in Kyoto University Graduate School of Medicine on trans-ethnic comparative human genomics
A clinical research partnership between Inserm and its partners and the Translational Research Center of Kyoto University.
A collaborative agreement with the Riken so as to foster our partnership in :
Stem cell biology (Riken CDB)
Immunology (Riken RCAI)
Neurosciences (Riken BSI)
DPRE-DRI
INSERM Unit
Associated Laboratory
In preparation
Tokyo
Kyoto
Tokyo
DPRE-DRI
Evaluation of participation of Inserm to the 6th FP as in March 2006
Inserm is involved in 99 projects (including coordination of 24 projects)
Graph2
Thématique I "Science de la vie, génomique, et biotechnologie pour la santé" : 82 Projets
Thématique II "Technologies de la Société de l'Information": 1 projet
Thématique III "Nanotechnologies" : 4 Projets
Thématique V "Sureté Alimentaire" : 4 Projets
Thématique "Sciences & Société" : 4 projets
Thématique Euratom : 1 Projet
Programme INCO : 1 Projet
REX
PI
STREP
SSA
CA
Total
REX
PI
STREP
SSA
CA
Total
Thématique I "Science de la vie, génomique, et biotechnologie pour la santé" : 82 Projets
82
5
2
11
2
0
20
13
27
18
1
3
62
Thématique II "Technologies de la Société de l'Information": 1 projet
1
0
1
0
0
0
1
0
0
0
0
0
0
4
0
0
0
0
0
0
1
2
1
0
0
4
4
0
0
0
0
0
0
2
2
0
0
0
4
4
0
0
0
1
0
1
1
0
0
1
1
3
Project preparation mainly within the FP6 programme : partnership with Inserm Transfert SA
The « Europe Task Force » actions:
Information and promotion
Coordination / partnership of Inserm
Follow-up of the next FP7 (Thematic priorities, JTI, …)
DPRE-DRI
Information
To represent Inserm at Brussels and near other European institutions
To follow European policies development and to evaluate opportunities
To set-up and coordinate bilateral cooperations
DPRE-DRI
Contact person in each connected/involved Inserm’ departments: The EUROPE Task Force
A permanent staff in Brussels (CLORA)
A contact in London
A specific budget
DRI
DRCT
CLORA
DFL
DRH
DAPS
END
- Lobbying
- Information
Administrative staffs
Projects' coordinators
Consortium agreements
Preparation & management
Universities
Inserm-Transfert
International
institutions
Pharmaceutical
companies
Pilot action under preparation with European institutions (Italy, Portugal, UK, Spain, Germany,..)
Permanent position by Inserm + temporary contract:
“2/3 base salary + 1/3 supplementation”
Co-funding strategy : one of the European Marie Curie schemes ?
DPRE-DRI
Extension of such programs to European mobility - Marie Curie Fellowship scheme ?
Heterogeneity of scientists career tracks: tenure positions provided by universities vs. research agencies etc…
However: the senior positions offered by each country may be viewed as a “core” status which salary can be maintained by the institution for scientists who wish to work in other countries.
As an incentive to mobility, the host institutions might add temporary grants (Interface grants) obtained by the scientist who moves to another country, provided by: hospitals, universities, industry, others…
Basis of the program: reciprocity, attractivity …
Future prospective :
a more "homogenized" tenure position career track: (salary, social security benefits and taxes, EU-wide health card etc.)
- Implication of European Marie Curie programs ?
DPRE-DRI
Contacts :
Department of French Regional and European Strategic Policies
Anne Bisagni, Director : [email protected]
Anne-Marie Laffaye, School of Inserm, Avenir : [email protected]
Richard Salives, Marie Curie Programme : [email protected]
DPRE-DRI
DPRE-DRI
1%
83%
biotechnologie pour la santé" : 82 Projets
Thématique II "Technologies de la Société de
l'Information": 1 projet
Thématique V "Sureté Alimentaire" : 4 Projets
Thématique "Sciences & Société" : 4 projets
Thématique Euratom : 1 Projet
Programme INCO : 1 Projet
0
2
4
6
8
10
12
14
16
18
20
2001200220032004200520062007
Années
320
330
340
350
360
370
380
Created in 1964 from the National Institute of Hygiene and Hospital Research
Working through the
DPRE-DRI
5 100 Inserm employees
335 Inserm laboratories
19 research centers
An active patent portfolio of 572 families
41 Clinical Investigation Centers (CIC)
56 start-up companies based on Inserm technology
DPRE-DRI
The French performing research organisation entirely dedicated to Biomedical & Clinical research and Public Health
All fields of research are covered in these domains
80% of the 354 research units are located in University hospitals
Research units with 8 years mandate with mid-term (4 year) evaluation. Stringent evaluation
Investigator- driven projects - AVENIR programme
Close collaboration with French Funding agencies (ANR, INCa ANRS), Sanitary agencies (InVS, AFSSAPS), Charities (AFM, …) and industrial partners.
DPRE-DRI
DPRE-DRI
Publications 1995-2005
(publications 1995 – 2005)
DPRE-DRI
New England Journal of Medicine (IF=44,016) , JAMA-Journal of the American Medical Association (23,494) and Lancet (23,878)
Science (IF=30,927) and Nature (IF=29,273)
Que les articles, ni lettres ni revues
DPRE-DRI
DPRE-DRI
DPRE-DRI
DPRE-DRI
New England Journal of Medicine (IF=44,016) , JAMA-Journal of the American Medical Association (23,494) and Lancet (23,878)
Science (IF=30,927) and Nature (IF=29,273)
Que les articles, ni lettres ni revues
DPRE-DRI
Organization
Networks focused on major public health issues
DPRE-DRI
7.5%
Handicap
5.1%
Nutrition
4.8%
AIDS
3.7%
Research laboratories being often involved in more that one domain, the overall distribution is over 100 %
DPRE-DRI
- INRIA
ex: CNG, Nanotechnology
Dedicated research Programmes :
Objectives and main characteristics:
Mutualisation and Integration
International visibility, Attractiveness
Sharing of technical facitilies
Implementation of research training programmes
International scientific council for evaluation of scientific strategy (turn-over of scientific teams : mobility, hosting new scientists or teams,…)
DPRE-DRI
Some exemples:
Graph2
2001
2001
2002
2002
2003
2003
2004
2004
2005
2005
2006
2006
2007
2007
347
2
350
4
357
5
361
6
366
8
373
9
340
19
données
Evolution des unités entre 2001 et 2007 (y compris CDR)
Années
2001
2002
2003
2004
2005
2006
2007
Années
2001
2002
2003
2004
2005
2006
2007
1) Nombre d'unités comprend les : unités, équipes, ERM, CDR
2) Nombre de CDR comprend les : unités quui sont considérés comme des CDR
&LInserm - DPRE
DPRE-DRI
National Sequencing Center
National Genotyping Center
Clinical Research Infrastructures
Competitivity clusters (Industry)
DPRE-DRI
International
National
Emergent
Main Inserm’s priorities
« Researchers » : Careers, Training & Mobility
To focus Inserm on its main mission: support both basic and clinical research; develop translational research with a multidisciplinary approach
To establish Inserm in a European and International context
To develop public/private partnerships
NEW CAREER TRACKS
To strengthen the status of young scientists; to recognize, evaluate and promote scientific qualities: high level fixed term contracts and the program AVENIR
To offer tenure positions to researchers: mid and long-term research plans
To increase research career development and mobility and foster partnerships:
INTERFACE RESEARCH GRANTS
30%: Avenir
Contrats post-doctorants 12 mois (24 mois ?)
(Postes verts)
3 ans de post-doctorat dans l’un des instituts des
NIH « intra-muros ».
de la qualité du stage post-doctoral
Contrat Junior (5ans, avec évaluation à 3 ans)
Contrat temporaire universitaire ou HU
Recrutement: EPST, Université etc ..
CR
DR
IR
Hôpital
HOPITAL
INSERM
evaluation), high level contracts
DPRE-DRI
Eligibility: Young scientists with permanent or temporary position, clinicians
Aim: To strengthen the status of young scientists; to recognize, evaluate and continuously promote scientific qualities
Each successful candidate is allocated:
A yearly budget of 60 K euros
Minimum lab space of 50 m2
Personnel: 1 post-graduate collaborator and 1 graduate student
Each successful young scientist receives a salary for 5 years
DPRE-DRI
Academic freedom
Health agencies
available to the society
European mobility ?
Hospitals: clinical research, medical issues
Health agencies: health policy issues
Universities: teaching, making scientific information available to the society
Industry: technological transfer and valorisation
European partners / European mobility (a new scheme of the Marie Curie actions - PEOPLE programme ?)
DPRE-DRI
CR
DR
Universities
Mount Sinai Medical School , New York, USA
Joint Inserm/AFM/Paris VI operation
Research theme: muscle development
Inserm Unit
Accompagnying measures:
Presently: Assistant professor, Dept of Medicine
University of Freiburg, Germany
Inserm/ULP/HUS Strasbourg joint operation
DR2 permanent position + Interphase contract HUS
Inserm unit, Avenir: in progress
Temporary contracts
Was: Clinical Scholar, Rockfeller University and Resident Clinical Pathology The New York Hospital New York, USA
Inserm/Pasteur Institute/Necker Hospital joint operation
Research theme: Dendritic cell biology/HCV/Cancer
Location: Pasteur Institute Paris
Since June 2003 : Inserm DR2 permanent position + Interphase contract AP-HP + Team Leader Pasteur Institute
Inserm Avenir Unit and Pasteur Institute Unit
Temporary contracts (junior scientists, MDs)
Assistance with housing
5 700 Inserm employees
325 Inserm laboratories
19 research centers
An active patent portfolio of 572 families
41 Clinical Investigation Centers (CIC)
56 start-up companies based on Inserm technology
DPRE-DRI
3-5 year contracts for clinicians : assistant professors and
professors, university employees
Grant paid by Inserm to hospitals and universities to be used for :
- clinical and teaching activities: temporary positions
- financing research activities
The School of Inserm
A 3 year Educational programme which leads to a Master and MD-PhD track
First year of Inserm School - Second year of Medical School :
Special School Intensive Training Session in February
June: Competitive Exam
Second year of Inserm School - Third year of Medical School
6 month full time Research Clerkship in an Inserm Research Laboratory
Third year of Inserm School - Interruption of Medical School : Clerkship in a Research Laboratory and educational program for the Master Degree
DPRE-DRI
To sponsor clinical studies and innovative therapeutic clinical trials
To ensure appropriate training of Physicians to Research skills and vice-versa
To integrate these actions in a European context:
ECRIN, Biological resource centers: Roadmap ESFRI
Innovative medecine platform
Translational research
To support development of new therapeutic molecules :
Innovative BASIC research approaches
in between : dedicated research infrastructures
To support Innovation and Biotechnology sector development
To satisfy end-users (patients) requirements
DPRE-DRI
Inserm, as a major actor of the Clinical Research in France and in Europe
To set-up an efficient Translational research towards the benefits of patients
To develop dedicated performing Research Infrastructures : ECRIN, GMP facilities platforms (innovative biomedicines), BRCs, (Roadmap ESFRI)
To sponsor clinical studies and innovative therapeutic clinical trials
To ensure appropriate training of Physicians to Research skills and vice-versa : School of Inserm
To built a continuum from Basic research to Clinical Research
DPRE-DRI
35
2006
< 2000
2000
2001
2002
2003
2004
2005
CIC-Biothérapie
Etudes et essais cliniques réalisées dans les CIC:
environ 20-30% viennent des unités
DPRE-DRI
CIC
Bichat
797 on-going Clinical trials
European and international multicentrics
About 320 000 patients expected to be included and 45 000 currently involved
120 beds devoted to clinical trials
A staff of professionals
DPRE-DRI
Gastro-Enterology-Hepatology : 9 CIC
Thrombosis : 3 CIC
Cancer
Neurosciences : 13 CIC
Paediatric : 8 CIC
DPRE-DRI
Pan-European network of Clinical research infrastructures: the ECRIN network of INSERM
ECRIN : European Clinical Research Infrastructures Network
France
EFGCP
ECRIN should be considered as a tool that will allow:
- to access research facilities certified as compliant with the GMP/GLP standards in Europe
- to access expertise in the preparation and conduct of trans-national clinical trials
- to access scientific and ethic evaluations
DPRE-DRI
to multinational studies
1 - interaction with ethics commitees
2 - interaction with competent authorities, regulatory affairs
3 - drug dispensing
DPRE-DRI
DPRE-DRI
BRCs in France
National policy of the Ministry for Research and the National Research Agency to support the development of BRCs
Lille
Caen
Rennes
Nantes
Tours
Nancy
Strasbourg
Lyon
Montpellier
Marseille
3
2
1
2
3
2
9
2
2
2
Dijon
1
Grenoble
2
Toulouse
2
Amiens
1
1
Angers
Brest
1
2
Reims
36
IDF
DPRE-DRI
Academic : valorisation, technology tranfer and dissemination of knowledge.
Biological Resources Centres
DPRE-DRI
"Service providers and repositories of the living cells, genomes of organisms, and information relating to heredity and the functions of biological systems" (O.E.C.D. definition).
Infrastructures that qualify biological samples (DNA, RNA, proteins…), provide samples for national projects and keep samples for the future (inheritage).
Biological Resources Centres
To co-ordinate European scientific programs and policies : 7th PCRD
To develop and harmonize assurance-quality standards for European BRCs : exchanges of authenticated biological materials.
Valorisation of knowledge
European Biological Resources network (EBRC)
DPRE-DRI
The European BRCs brings together:
Service and work facilities made up of collections that satisfy the EU research objectives
Conservation sites made up of patrimonial reference collections : national collections, cryobanks, rare tissue or tumour collections…
Ongoing European initiatives :
Access to "thematic" cohorts of patients (cancer, mental diseases, etc.)
Access to cohorts of healthy volunteers for prospective studies, genetic studies, etc.
The Challenges of Biomarkers
Bio-pharmaceutical industry : Valorisation of Research in partnership with industry.
DPRE-DRI
Platforms for production of therapeutic virus : Heidelberg
Perspectives : availability of GMP products
Partnership with Inserm-Transfert
IMI : Innovative Medicines for Europe
European Joint Technology Initiative (JTI) to develop new therapeutic drugs in a faster and safer way.
Inserm is the French representative in the Member states contact Group of IMI
DPRE-DRI
Organization
Networks focused on major public health issues
DPRE-DRI
National Research Programs
To bring together all parties interested in a given research area:
Research institutes
Industry
To launch calls for proposals open to the scientific community regardless of institutional affiliation
To support young investigators, scientists and clinicians
DPRE-DRI
To support new/young research teams
To support organisation of seminars and workshops : prospective studies and follow-up of actions
To identify projects that could be submitted to FP7 or some other international programmes (NIH, etc
Collaborations with the NIH: seminars and grants
To reinforce partnerships with
National Research Program on Diabetes PNRD
in collaboration with CNRS
in collaboration with INRA
Virtual Institute for Public Health Research IVRSP
National Research Program on sense organs PNRV
DPRE-DRI
PNRD
PNRC
PRNH
National Research Agency (ANR)
Created in February 2005 with a total yearly budget: around 800 M€ (approx. 25 % dedicated to Biomedical sciences)
Main objectives :
Launched calls for thematic and "free" programmes :
Cardiovascular diseases, Obesity, Diabetes
Neurosciences, psychiatry
Microbiology- Immunology
Rare diseases
Projects of scientific excellence : 370 k€ for a 3-year duration and involving 3 to 4 partners (in average)
DPRE-DRI
5652 proposals submitted
Breakdown of budget available / scientific domains :
30% Non-thematic
Specific actions and support to Partnership & Competitiveness, Young researchers (including chairs of excellence)
DPRE-DRI
In 2005 Cardiovascular, Obesity, Diabetes
Neurosciences, neurology and psychiatry
Neurosciences, neurology and psychiatry
Microbiology- Immunology- Emerging diseases
Biological Resources sampling in Health
DPRE-DRI
DPRE-DRI
DPRE-DRI
DPRE-DRI
Participation in European programmes : RTD FP & Public Health FP
Infrastructures - ESFRI (ECRIN, …)
Bilateral actions: Common Research projects - Associated laboratories - Joint-units abroad
DPRE-DRI
Inserm and
Inserm and
(2007 - 2013)
Inserm-Transfert SA
Private subsidiary of the French National Institute for Health and Medical Research (Inserm)
Created by Inserm in 2001, funded up to 4,5 M€ by Inserm and comprising actually 50 people
Increase researchers’ awareness of technology transfer and company creation
Identification and promotion of innovative projects emerging from Inserm’s laboratories
Launch of a new seed fund called “Inserm-Transfert Initiative” with three major investors in the biotech field (Sofinnova, Ventech, CDC Entreprise) - Capital amount = 4.2 M€
DPRE-DRI
International project management
21 projects under management (6 Network of Excellence, 3 Integrated Projects, 12 STREP) and 8 projects under negociation
Total budget for all projects under management over 200 million €
Creation of value by up-coming licensing and SME’s participation
Inserm-Transfert has invested 800 kEuros in 11 new biotech companies that have raised 85 million euros
600 patents' family - 60 to 90 New demands/year - 480 licensing agreements
Biotech start-up creation and Patenting
DPRE-DRI
Research networks ( EU programmes , NIH, Bill Gates etc..)
Associated laboratories
Researchers' mobility (short-medium term, Interface Contract grants)
European research networks at the bilateral level and within the EU programmes
European Associated laboratories
Cooperations between Inserm and German Partners (1)
One formal agreement with DFG : short-term exchange of researchers based on 2 years projects
538 cooperation undertaken since 1985
Main city: Berlin, Bonn, Munich, Freiburg, Heidelberg
Main thematic areas : Cellular Biology,Neurosciences, Immunology, Cancer, Genomics, Cardiovascular diseases,…
51 German Post-doc, Researchers and Fellows in the Inserm's research units in 2005
Cooperation with Freiburg:
DPRE-DRI
Cooperations between Inserm and German Partners (2)
Associated laboratories under preparation (HEGP/La Charité - Freiburg/Strasbourg)
A Joint Unit Abroad - U701 Inserm / DKFZ (J. Rommelaere - Heidelberg) - Cancer and Virotherapy
In the frame of the 6th EU Framework programme :
59 European research projects mainly in the LSH priority : 16 NoE - 27 IP - 14 STREPs - 2 CA (84 Inserm's teams - 83 German teams
Future collaborations within the FP7 :
Health priority, IMI, Infrastructures (ECRIN, BRCs)
DPRE-DRI
*
=> more than 61 common publications
Main cities: Budapest, Szeged, Debrecen
Main Partner Institutions : Hungarian Academy of Sciences, Semmelweis University, University of Debrecen etc.
Main thematic areas : Neurosciences, Cellular Biology, Molecular Biology, Cardiovascular Physiopathology, Biochemistry…
10 Hungarian Post-docs, Researchers and Fellows within Inserm's research units in 2005
DPRE-DRI
In the frame of the 6th EU Framework programme :
13 European research projects mainly in the LSH priority : 5 NoEs - 7 IPs - 1 STREP
(17 Inserm's teams - 14 +Hungarian teams)
Future collaborations within the FP7 :
Health priority, IMI, Infrastructures (ECRIN, BRCs)
*
DPRE-DRI
Co-funding by Inserm and Associated partners
Temporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts)
Networks, EU research projects
Co-funding by Inserm and Associated partners
Temporary/permanent positions (Mobility of Post-Doc, researchers - Interface contracts)
EU research projects - Networks
Lille : M. Capron U547 / Bruxelles : M. Goldman (IMI)
Associated laboratories
(under preparation)
Milan / Bordeaux
Rome / Villejuif
Rome / Nice
Ferrara / Paris
Dundee / Toulouse
Freiburg / Strasbourg
Berlin / Paris
Barcelona / Paris
Porto / Toulouse
Université de Glasgow / C. Doerig U609
DKFZ / J. Rommelaere U701
Glasgow University / C. Doerig (Inserm U609)
DKFZ / J. Rommelaere (Inserm U701)
European Associated Laboratories (LEA)
Lille Brussels:
M. Capron (Inserm U547) - M. Goldman (Univ. Libre de Bruxelles)
Toulouse Dundee:
Bordeaux Milan:
A. Bikfalvi (Inserm E 113) - L. Bello (Univ. Degli Studi)
Nice Rome:
Villejuif Paris Sud Rome:
D. Samuel (Inserm U 785) - M. Levrero (Univ. La Sapienza)
Montpellier London:
K. Ritchie (Inserm U 888) - G. Thornicroft (King’s College of London)
Strasbourg Freiburg:
T. Baumert (Inserm U 748) - H. Blum (Univ. of Freiburg)
Villejuif Paris Sud Barcelona:
Bordeaux Porto:
DPRE-DRI
Montréal
Pittsburgh
Pilot action under preparation
“2/3 base salary + 1/3 supplementation”
DPRE-DRI
Japan is the first partner of Inserm in Asia (ca. 180 collaborative projects).
An increase between 2000 and 2006 (+40%).
About 20 Japanese scientists within Inserm units each year.
2% of Inserm publications are with Japan.
Long term relationship Inserm-JSPS : 80 projects funded since 1994
Inserm-Japan
DPRE-DRI
International Associated laboratory with the RIKEN DRI on lipidomics study of membrane microdomains.
Inserm Unit in Kyoto University Graduate School of Medicine on trans-ethnic comparative human genomics
A clinical research partnership between Inserm and its partners and the Translational Research Center of Kyoto University.
A collaborative agreement with the Riken so as to foster our partnership in :
Stem cell biology (Riken CDB)
Immunology (Riken RCAI)
Neurosciences (Riken BSI)
DPRE-DRI
INSERM Unit
Associated Laboratory
In preparation
Tokyo
Kyoto
Tokyo
DPRE-DRI
Evaluation of participation of Inserm to the 6th FP as in March 2006
Inserm is involved in 99 projects (including coordination of 24 projects)
Graph2
Thématique I "Science de la vie, génomique, et biotechnologie pour la santé" : 82 Projets
Thématique II "Technologies de la Société de l'Information": 1 projet
Thématique III "Nanotechnologies" : 4 Projets
Thématique V "Sureté Alimentaire" : 4 Projets
Thématique "Sciences & Société" : 4 projets
Thématique Euratom : 1 Projet
Programme INCO : 1 Projet
REX
PI
STREP
SSA
CA
Total
REX
PI
STREP
SSA
CA
Total
Thématique I "Science de la vie, génomique, et biotechnologie pour la santé" : 82 Projets
82
5
2
11
2
0
20
13
27
18
1
3
62
Thématique II "Technologies de la Société de l'Information": 1 projet
1
0
1
0
0
0
1
0
0
0
0
0
0
4
0
0
0
0
0
0
1
2
1
0
0
4
4
0
0
0
0
0
0
2
2
0
0
0
4
4
0
0
0
1
0
1
1
0
0
1
1
3
Project preparation mainly within the FP6 programme : partnership with Inserm Transfert SA
The « Europe Task Force » actions:
Information and promotion
Coordination / partnership of Inserm
Follow-up of the next FP7 (Thematic priorities, JTI, …)
DPRE-DRI
Information
To represent Inserm at Brussels and near other European institutions
To follow European policies development and to evaluate opportunities
To set-up and coordinate bilateral cooperations
DPRE-DRI
Contact person in each connected/involved Inserm’ departments: The EUROPE Task Force
A permanent staff in Brussels (CLORA)
A contact in London
A specific budget
DRI
DRCT
CLORA
DFL
DRH
DAPS
END
- Lobbying
- Information
Administrative staffs
Projects' coordinators
Consortium agreements
Preparation & management
Universities
Inserm-Transfert
International
institutions
Pharmaceutical
companies
Pilot action under preparation with European institutions (Italy, Portugal, UK, Spain, Germany,..)
Permanent position by Inserm + temporary contract:
“2/3 base salary + 1/3 supplementation”
Co-funding strategy : one of the European Marie Curie schemes ?
DPRE-DRI
Extension of such programs to European mobility - Marie Curie Fellowship scheme ?
Heterogeneity of scientists career tracks: tenure positions provided by universities vs. research agencies etc…
However: the senior positions offered by each country may be viewed as a “core” status which salary can be maintained by the institution for scientists who wish to work in other countries.
As an incentive to mobility, the host institutions might add temporary grants (Interface grants) obtained by the scientist who moves to another country, provided by: hospitals, universities, industry, others…
Basis of the program: reciprocity, attractivity …
Future prospective :
a more "homogenized" tenure position career track: (salary, social security benefits and taxes, EU-wide health card etc.)
- Implication of European Marie Curie programs ?
DPRE-DRI
Contacts :
Department of French Regional and European Strategic Policies
Anne Bisagni, Director : [email protected]
Anne-Marie Laffaye, School of Inserm, Avenir : [email protected]
Richard Salives, Marie Curie Programme : [email protected]
DPRE-DRI
DPRE-DRI
1%
83%
biotechnologie pour la santé" : 82 Projets
Thématique II "Technologies de la Société de
l'Information": 1 projet
Thématique V "Sureté Alimentaire" : 4 Projets
Thématique "Sciences & Société" : 4 projets
Thématique Euratom : 1 Projet
Programme INCO : 1 Projet
0
2
4
6
8
10
12
14
16
18
20
2001200220032004200520062007
Années
320
330
340
350
360
370
380